Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033455 | 0.92 | IRAK4 (0.43) | IRAK4KDM4EPKMHSD17B10IRAK1 | |
| SCHEMBL14033296 | 0.90 | PDE2A (0.43) | IRAK4IRAK1PDE2AJAK2JAK1 | |
| SCHEMBL14033696 | 0.89 | IRAK4 (0.42) | IRAK4KDM4EPKMHSD17B10IRAK1 | |
| SCHEMBL4437012 | 0.86 | KLKB1 (0.42) | IRAK4KDM4EIRAK1PDE2AJAK2 | |
| SCHEMBL14033447 | 0.84 | HSD17B10 (0.47) | IRAK4KDM4EPKMHSD17B10PDE2A | |
| SCHEMBL14033169 | 0.84 | PDE2A (0.42) | IRAK4KDM4EPKMHSD17B10IRAK1 | |
| SCHEMBL4439750 | 0.83 | PDE2A (0.41) | IRAK4KDM4EPKMHSD17B10IRAK1 | |
| SCHEMBL4437368 | 0.82 | MRGPRX4 (0.42) | KDM4EPKMHSD17B10PDE2A | |
| SCHEMBL4434781 | 0.79 | NR3C1 (0.47) | IRAK4KDM4EPKMHSD17B10PDE2A | |
| SCHEMBL14033962 | 0.77 | PDE2A (0.44) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | IRAK4 1203/4885KDM4E 1192/4885PKM 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.